and Pfizer’s Elrexfio (elranatamab), which have both been cleared by the FDA for relapsed or refractory multiple myeloma. The top-line efficacy data with Regeneron’s drug looks a little ...

Reports continued progress in the evaluation of assets for potential in-licensing and development in the areas of oncology and rare disease - - New data from pilot ...